Published on : Jun 15, 2016
ALBANY, New York, June 15, 2016: ResearchMoz.us has recently announced the addition of a market study on the global hematological market, according to which, the global hematological cancer market is expected to rise at a CAGR of 12.5% during the period from 2015 to 2022.
The report, titled “Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market,” states that this market is likely to rise from a value of US$30.7 bn in 2015 to US$70.1 bn by the end of the forecast period.
It presents a comprehensive analysis of this market by evaluating the route of administration (RoA) and mechanism of action (MoA) in hematological cancer therapeutics and states that the clinical trials of hematological cancer therapeutics have an overall attrition rate of 70.3%.
This 147-page market study is prepared by sourcing data from SEC filings, the websites of the participants in the global hematological cancer market, presentations by investors, press releases, and market-specific third party sources. It also analyzes this market on the basis of targeted therapies. The current hematological cancer therapeutics pipeline consists of 1,207 active products.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=725318
This study is an attempt to estimate the size of the overall market for hematological cancer at present and in the coming years. It also mentions the growth rate on which the market has been rising over the last few years. It further identifies the key trends such as driving forces, limitations, challenges, and opportunities in this market.
The report studies all the inactive and dormant pipeline projects and provides important information about peers to formulate efficient research and design growth strategies. It also identifies the emerging hematological cancer market participants with a potentially strong product portfolio and analyzes the significant and varied types of therapeutics under development for the treatment of hematological cancer.
Apart from these, several in-licensing and out-licensing strategies have also been designed in this report by identifying potential partners with attractive projects. Remedial measures for pipeline projects have also been created by understanding the depth and center of indication of the therapeutic market for hematological cancer.
The competitive landscape of the global hematological cancer market has also been examined in this study by profiling the major participants. Hoffmann-La Roche, Novartis, Celgene, Millennium Pharmaceuticals, Johnson & Johnson, Bristol-Myers Squibb, Otsuka Pharmaceutical, Onyx Pharmaceuticals, Amgen Inc., Seattle Genetics, and AbbVie Inc. are the key market players profiled in this research report.
The prime objective of this research study is to assist stakeholders in the global market for hematological cancer in creating efficient counter strategies and enhancing their decision-making abilities to gain a competitive edge over their peers.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org